Cisplatin nausea/vomiting with, aprepitant

Current published information describes the experience with aprepitant in highly emetogenic cisplatin-based chemotherapy regimens. The NCCN has also included aprepitant for prophylaxis of nausea and vomiting induced by moderately emetogenic chemotherapy regimens. This recommendation is not supported by the current literature and has been questioned by clinicians. 

Aprepitant is the first approved member of this class of drugs and is indicated as part of a multiple drug regimen for prophylaxis of nausea and vomiting associated with high-dose cisplatin-based chemotherapy. 

Antiemetic Aprepitant, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, including high-dose cisplatin. 

---